Effect of Acute Decompensation(complication of liver disease) in Patients with liver disease
Not Applicable
- Conditions
- Health Condition 1: null- Acute Decompensation in CirrhosisHealth Condition 2: K746- Other and unspecified cirrhosis ofliver
- Registration Number
- CTRI/2018/03/012321
- Lead Sponsor
- Institute of liver and Biliary Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Other (Terminated)
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Cirrhosis with decompensation in a period of 3 months in form of ascites, jaundice, HepaticEncephalopathy, Acute Variceal bleed irrespective of prior decompensation.
2.Age 18-70 years
3.Valid consent
Exclusion Criteria
1.HepatoCellular Carcinoma
2.Admitted and survival less than 48 hrs
3.Pregnant
4.Acute Liver Failure
5.Post Transplant
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Spontaneous recovery, liver transplant or death in 90 daysTimepoint: 90 days
- Secondary Outcome Measures
Name Time Method Cause of acute decompensation.Timepoint: 90 days;Causes of deathTimepoint: 90 days;Improvement in severity assessment Indices (MELD, CTP, SOFA, APACHE II and CLIF SOFA scores)Timepoint: 90 days;Profile of patient undergone transplantTimepoint: 90 days;Sepsis, SIRS and infectionTimepoint: 90 days;Severity and duration of prior as well as present decompensationTimepoint: 90 days
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are implicated in acute decompensation of cirrhosis as studied in CTRI/2018/03/012321?
How does prior decompensation status affect survival outcomes in cirrhosis patients with acute decompensation?
Which serum biomarkers correlate with acute decompensation severity in K746 cirrhosis subtypes?
What are the most effective management strategies for hepatic encephalopathy in acute decompensation of cirrhosis?
Are there emerging therapeutic targets for acute-on-chronic liver failure (ACLF) in cirrhosis beyond standard care?